Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 14 | 2024 | 2593 | 2.750 |
Why?
|
| Shock, Septic | 6 | 2023 | 775 | 2.160 |
Why?
|
| Resuscitation | 3 | 2019 | 658 | 1.320 |
Why?
|
| Renin-Angiotensin System | 5 | 2022 | 759 | 1.010 |
Why?
|
| Intensive Care Units | 5 | 2020 | 3679 | 0.930 |
Why?
|
| Hypotension | 3 | 2018 | 884 | 0.920 |
Why?
|
| Angiotensin II | 2 | 2022 | 881 | 0.820 |
Why?
|
| Hospital Mortality | 7 | 2023 | 5317 | 0.750 |
Why?
|
| Endothelium | 1 | 2022 | 778 | 0.680 |
Why?
|
| Critical Illness | 5 | 2021 | 2670 | 0.680 |
Why?
|
| Pulmonary Alveoli | 1 | 2022 | 675 | 0.670 |
Why?
|
| Myeloid Cells | 1 | 2022 | 810 | 0.600 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 119 | 0.600 |
Why?
|
| Critical Care | 2 | 2020 | 2647 | 0.570 |
Why?
|
| Propofol | 1 | 2023 | 629 | 0.570 |
Why?
|
| Bacteremia | 2 | 2022 | 962 | 0.540 |
Why?
|
| Interleukin-6 | 3 | 2024 | 3200 | 0.500 |
Why?
|
| Hypertension | 4 | 2022 | 8480 | 0.490 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 722 | 0.490 |
Why?
|
| Multiple Organ Failure | 3 | 2022 | 390 | 0.460 |
Why?
|
| Guideline Adherence | 3 | 2023 | 2266 | 0.460 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2016 | 859 | 0.460 |
Why?
|
| Biological Products | 1 | 2022 | 860 | 0.450 |
Why?
|
| Causality | 1 | 2019 | 1275 | 0.410 |
Why?
|
| Propensity Score | 1 | 2019 | 1781 | 0.410 |
Why?
|
| Fluid Therapy | 1 | 2016 | 593 | 0.410 |
Why?
|
| Periodicals as Topic | 2 | 2020 | 1432 | 0.410 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 612 | 0.400 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2022 | 152 | 0.380 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 7659 | 0.370 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 1972 | 0.360 |
Why?
|
| Inpatients | 1 | 2019 | 2518 | 0.300 |
Why?
|
| Thrombosis | 1 | 2020 | 2968 | 0.270 |
Why?
|
| Blood Pressure | 3 | 2023 | 8554 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 7181 | 0.270 |
Why?
|
| Hospitals | 1 | 2019 | 3952 | 0.260 |
Why?
|
| Models, Statistical | 1 | 2020 | 5102 | 0.260 |
Why?
|
| Thiadiazoles | 1 | 2024 | 55 | 0.240 |
Why?
|
| Respiration, Artificial | 3 | 2022 | 2569 | 0.230 |
Why?
|
| Cecum | 2 | 2024 | 237 | 0.230 |
Why?
|
| Ligation | 2 | 2024 | 453 | 0.230 |
Why?
|
| Biomedical Research | 1 | 2019 | 3309 | 0.220 |
Why?
|
| Punctures | 2 | 2024 | 374 | 0.220 |
Why?
|
| Humans | 31 | 2023 | 744343 | 0.210 |
Why?
|
| Adrenergic Agents | 1 | 2022 | 70 | 0.210 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 2624 | 0.210 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2014 | 236 | 0.210 |
Why?
|
| Prevalence | 5 | 2019 | 15226 | 0.200 |
Why?
|
| Vital Signs | 1 | 2023 | 142 | 0.200 |
Why?
|
| Losartan | 2 | 2020 | 299 | 0.200 |
Why?
|
| Angiotensins | 1 | 2022 | 151 | 0.200 |
Why?
|
| Hospitalization | 2 | 2020 | 10262 | 0.200 |
Why?
|
| APACHE | 2 | 2020 | 277 | 0.200 |
Why?
|
| Lisinopril | 1 | 2020 | 54 | 0.190 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2020 | 67 | 0.190 |
Why?
|
| Length of Stay | 4 | 2017 | 6309 | 0.180 |
Why?
|
| Bone Wires | 1 | 2020 | 122 | 0.180 |
Why?
|
| Renin | 1 | 2022 | 642 | 0.180 |
Why?
|
| Feedback | 1 | 2023 | 795 | 0.180 |
Why?
|
| Norepinephrine | 1 | 2022 | 909 | 0.180 |
Why?
|
| Vasopressins | 1 | 2021 | 370 | 0.180 |
Why?
|
| Prospective Studies | 6 | 2023 | 53288 | 0.170 |
Why?
|
| Anesthetics, Intravenous | 1 | 2023 | 417 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 2716 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 365 | 0.160 |
Why?
|
| Time Factors | 7 | 2020 | 40075 | 0.150 |
Why?
|
| Cytokines | 2 | 2024 | 7322 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2019 | 23338 | 0.150 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2022 | 1240 | 0.140 |
Why?
|
| Aged | 10 | 2022 | 163280 | 0.140 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 924 | 0.140 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 155 | 0.130 |
Why?
|
| Coronary Thrombosis | 1 | 2019 | 495 | 0.130 |
Why?
|
| Cost Savings | 2 | 2019 | 926 | 0.130 |
Why?
|
| Intubation, Intratracheal | 1 | 2023 | 1364 | 0.120 |
Why?
|
| Prosthesis-Related Infections | 1 | 2020 | 538 | 0.120 |
Why?
|
| Syndrome | 1 | 2021 | 3251 | 0.120 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 690 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1518 | 0.120 |
Why?
|
| Steroids | 1 | 2019 | 930 | 0.110 |
Why?
|
| Male | 14 | 2024 | 350118 | 0.110 |
Why?
|
| Interferon-gamma | 1 | 2022 | 3206 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 57776 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 2046 | 0.110 |
Why?
|
| Echocardiography | 2 | 2016 | 5102 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 1451 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 15540 | 0.100 |
Why?
|
| Female | 13 | 2022 | 380194 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 1405 | 0.100 |
Why?
|
| Pyridines | 1 | 2024 | 2825 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 19905 | 0.100 |
Why?
|
| Heart Rate | 1 | 2023 | 4091 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2017 | 1133 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 804 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 788 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2020 | 1400 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 18029 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1462 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 5524 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2020 | 1139 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 21827 | 0.090 |
Why?
|
| ROC Curve | 1 | 2018 | 3527 | 0.090 |
Why?
|
| Fever | 1 | 2017 | 1616 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 1956 | 0.090 |
Why?
|
| Patient Admission | 1 | 2017 | 1380 | 0.090 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 981 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4933 | 0.080 |
Why?
|
| Middle Aged | 7 | 2022 | 213383 | 0.080 |
Why?
|
| Heart Arrest | 1 | 2019 | 1470 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2021 | 8324 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2019 | 63114 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 2148 | 0.080 |
Why?
|
| Mice | 4 | 2024 | 81183 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2020 | 77449 | 0.070 |
Why?
|
| Consensus | 1 | 2016 | 2959 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 3158 | 0.070 |
Why?
|
| Prognosis | 2 | 2020 | 29063 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 3068 | 0.070 |
Why?
|
| Curriculum | 1 | 2018 | 3605 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 2337 | 0.060 |
Why?
|
| Animals | 6 | 2024 | 168757 | 0.060 |
Why?
|
| Comorbidity | 1 | 2019 | 10388 | 0.060 |
Why?
|
| Chemokine CCL3 | 1 | 2024 | 83 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 10180 | 0.060 |
Why?
|
| Inflammation | 2 | 2022 | 10638 | 0.060 |
Why?
|
| Cholinergic Agents | 1 | 2024 | 93 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12245 | 0.060 |
Why?
|
| Survival Rate | 1 | 2017 | 12788 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2020 | 21746 | 0.050 |
Why?
|
| Risk Factors | 4 | 2019 | 72290 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 9959 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Logistic Models | 1 | 2017 | 13408 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2017 | 7729 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2017 | 3749 | 0.050 |
Why?
|
| Endotoxins | 1 | 2024 | 527 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2013 | 3821 | 0.050 |
Why?
|
| United States | 3 | 2019 | 69872 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2024 | 648 | 0.050 |
Why?
|
| Phenotype | 1 | 2018 | 16365 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 18370 | 0.050 |
Why?
|
| Bacterial Load | 1 | 2020 | 153 | 0.040 |
Why?
|
| Adult | 3 | 2023 | 214055 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.040 |
Why?
|
| Chemokines | 1 | 2024 | 970 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2022 | 23403 | 0.040 |
Why?
|
| Child | 3 | 2016 | 77709 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2020 | 15295 | 0.040 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2020 | 451 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 1588 | 0.040 |
Why?
|
| Algorithms | 1 | 2017 | 13881 | 0.030 |
Why?
|
| Biofilms | 1 | 2020 | 617 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 39050 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 40561 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 41006 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 2216 | 0.030 |
Why?
|
| Heart Failure | 1 | 2017 | 10900 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2020 | 2617 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4420 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 753 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 3339 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 1477 | 0.020 |
Why?
|
| Drug Costs | 1 | 2019 | 1105 | 0.020 |
Why?
|
| Creatinine | 1 | 2016 | 1919 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 4479 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 1 | 2016 | 706 | 0.020 |
Why?
|
| Adolescent | 2 | 2014 | 85781 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
| Neutrophils | 1 | 2020 | 3719 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 56430 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2019 | 3461 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2016 | 2044 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 5391 | 0.020 |
Why?
|
| Linear Models | 1 | 2016 | 5952 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 8089 | 0.010 |
Why?
|
| Brain | 1 | 2024 | 26385 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 25625 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 35136 | 0.010 |
Why?
|
Concepts
(180)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_